Augmented cellular uptake and antiproliferation against pancreatic cancer cells induced by targeted curcumin and SPION encapsulated PLGA nanoformulation

Materials Express

Volumn 4, Issue 3, 2014, Pages 183-195

  Sivakumar, Balasubramanian ^a   Aswathy, Ravindran Girija ^a   Nagaoka, Yutaka ^a   Iwai, Seiki ^a   Hasumura, Takashi ^a   Venugopal, Kizhikkilot ^b   Kato, Kazunori ^a   Yoshida, Yasuhiko ^a   Maekawa, Toru ^a   Sakthikumar, Dasappan Nair ^a  

^a TOYO UNIVERSITY   (Japan)

^b Sooriya Hospital   (India)

Author keywords

Curcumin; Nanotechnology; Pancreatic Cancer; PLGA Nanoparticles; SPIONs; Targeted Drug Delivery

Indexed keywords

EID: 84901784980     PISSN: 21585849     EISSN: 21585857     Source Type: Journal    
DOI: 10.1166/mex.2014.1160     Document Type: Article

References (45)

1. D. Li, K. Xie, R. Wolff, and J. L. Abbruzzese; Pancreatic cancer; Lancet 363, 1049 (2004).
2. F. Eckel, G. Schneider, and R. M. Schmid; Pancreatic cancer: A review of recent advances; Expert. Opin. Investig. Drugs 15, 1395 (2006).
3. S. Matsuno, S. Egawa, S. Fukuyama, F. Motoi, M. Sunamura, S. Isaji, T. Imaizumi, S. Okada, H. Kato, K. Suda, A. Nakao, T. Hiraoka, R. Hosotani, and K. Takeda; Pancreatic cancer registry in Japan: 20 years of experience; Pancreas 28, 219 (2004).
4. P. W. Pisters, R. A. Wolff, C. H. Crane, and D. B. Evans; Combined-modality treatment for operable pancreatic adenocarcinoma; Oncology 19, 393 (2005).
5. A. Halbreich, J. Roger, J. N. Pons, D. Geldwerth, M. F. Da Silva, M. Roudier, and J. C. Bacri; Biomedical applications of maghemite ferrofluid; Biochimie 80, 379 (1998).
6. D. R. Baselt, G. U. Lee, K. M. Hansen, L. A. Chrisey, and R. J. Colton; A high-sensitivity micromachined biosensor; Proc. IEEE. 85, 672 (1997).
7. I. Safarik and M. Safarikova; Use of magnetic techniques for the isolation of cells; J. Chromatogr. B: Biomed. Sci. Appl. 722, 33 (1999).
8. S. K. Pulfer, S. L. Ciccotto, and J. M. Gallo; Distribution of small magnetic particles in brain tumor-bearing rats; J. Neurooncol. 41, 99 (1999).
9. A. Jahnke, J. Hirschberger, C. Fischer, T. Brill, R. Köstlin, C. Plank, H. Küchenhoff, S. Krieger, K. Kamenica, and U. Schillinger; Intratumoral gene delivery of feIL-2, feIFN-gamma and feGM-CSF using magnetofection as a neoadjuvant treatment option for feline fibrosarcomas: A phase-I study; J. Vet. Med. A. Physiol. Pathol. Clin. Med. 54, 599 (2007).
10. C. Hüttinger, J. Hirschberger, A. Jahnke, R. Kostlin, T. Brill, C. Plank, H. Kuchenhoff, S. Krieger, and U. Schillinger; Neoadjuvant gene delivery of feline granulocyte-macrophage colonystimulating factor using magnetofection for the treatment of feline fibrosarcomas: A phase I trial. J. Gene. Med. 10, 655 (2008).
11. K. J. Widder, A. E. Senyei, and D. F. Ranney; Magnetically responsive microspheres and other carriers for the biophysical targeting of antitumor agents; Adv. Pharmacol. Chemother. 16, 213 (1979).
12. D. Leszczynski; Rapporteur report: Cellular, animal and epidemiological studies of the effects of static magnetic fields relevant to human health; Prog. Biophys. Mol. Biol. 87, 247 (2005).
13. S. Goodwin, C. Peterson, C. Hoh, and C. Bittner; Targeting and retention of magnetic targeted carriers (MTCs) enhancing intraarterial chemotherapy; J. Magn. Mater. 194, 132 (1999).
14. U. O. Hafeli; Magnetically modulated therapeutic systems; Int. J. Pharm. 277, 19 (2004).
15. C. Alexiou, A. Schmidt, R. Klein, P. Hulin, C. Bergemann, and W. Arnold; Magnetic drug targeting: Biodistribution and dependency on magnetic field strength; J. Magn. Magn. Mater. 252, 363 (2002).
16. Y. R. Chemla, H. L. Grossman, Y. Poon, R. McDermott, R. Stevens, M. D. Alper, and J. Clarke; Ultrasensitive magnetic biosensor for homogeneous immunoassay; Proc. Natl. Acad. Sci. USA 97, 14268 (2000).
17. J. P. Fortin, C. Wilhelm, J. Servais, C. Menager, J. C. Bacri, and F. Gazeau; Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia; J. Am. Chem. Soc. 129, 2628 (2007).
18. K. Briley-Saebo, A. Bjørnerud, D. Grant, H. Ahlstrom, T. Berg, and G. M. Kindberg; Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: Implications for magnetic resonance imaging; Cell. Tissue. Res. 316, 315 (2004).
19. R. Hergt, R. Hiergeist, I. Hilger, W. A. Kaiser, Y. Lapatnikov, S. Margel, and U. Richter; Maghemite nanoparticles with very high AC-losses for application in RF-magnetic hyperthermia; J. Magn. Magn. Mater. 270, 345 (2004).
20. D. D. Stark, R. Weissleder, G. Elizondo, P. F. Hahn, S. Saini, L. E. Todd, J. Wittenberg, and J. T. Ferrucci; Superparamagnetic iron oxide: Clinical application as a contrast agent for MR imaging of the liver; Radiology 168, 297 (1988).
21. J. M. Ringman, S. A. Frautschy, G. M. Cole, D. L. Masterman, J. L. Cummings; A potential role of the curry spice curcumin in Alzheimer's disease; Curr. Alzheimer. Res. 2, 131 (2005).
22. J. Ravindran, S. Prasad, and B. B. Aggarwal; Curcumin and cancer cells: How many ways can curry kill tumor cells selectively?; AAPS J. 11, 495 (2009).
23. B. B. Aggarwal, A. Kumar, and A. C. Bharti; Anticancer potential of curcumin: Preclinical and clinical studies; Anticancer. Res. 23, 363 (2003).
24. M. S. Cartiera, E. C. Ferreira, C. Caputo, M. E. Egan, M. J. Caplan, and W. M. Saltzman; Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin; Mol. Pharm. 7, 86 (2010).
25. A. Goel, A. B. Kunnumakkara, and B. B. Aggarwal; Curcumin as "Curecumin:" From kitchen to clinic. Biochem. Pharmacol. 75, 787 (2008).
26. A. S. Strimpakos and R. A. Sharma; Curcumin: Preventive and therapeutic properties in laboratory studies and clinical trials; Antioxid. Redox Signaling 10, 511 (2008).
27. M. W. Saif; Is there a role for herbal medicine in the treatment of pancreatic cancer? Highlights from the "44th ASCO Annual Meeting. " Chicago, IL, USA. May 30-June 3; JOP 9, 403 (2008).
28. T. Golombick, T. H. Diamond, V. Badmaev, A. Manoharan, and R. Ramakrishna; The potential role of curcumin in patients with monoclonal gammopathy of undefined significance its effect on paraproteinemia and the urinary N-telopeptide of type I collagen bone turnover marker; Clin. Cancer. Res. 15, 5917 (2009).
29. F. Esmaeili, M. H. Ghahremani, B. Esmaeili, M. R. Khoshayand, F. Atyabi, and R. Dinarvand; PLGA nanoparticles of different surface properties: Preparation and evaluation of their body distribution; Int. J. Pharm. 349, 249 (2008).
30. M. S. Shive and J. M. Anderson; Biodegradation and biocompatibility of PLA and PLGA microspheres; Adv. Drug Deliv. Rev. 28, 5 (1997).
31. J. M. Lu, X. Wang, C. Marin-Muller, H. Wang, P. H. Lin, Q. Yao, and C. Chen; Current advances in research and clinical applications of PLGA-based nanotechnology; Expert. Rev. Mol. Diagn. 9, 325 (2009).
32. K. Kimura, T. Sawada, M. Komatsu, M. Inoue, K. Muguruma, T. Nishihara, Y. Yamashita, N. Yamada, M. Ohira, and K. Hirakawa; Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine; Clin. Cancer. Res. 12, 4925 (2006).
33. G. Arya, M. Vandana, S. Acharya, and S.K. Sahoo; Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy; Nanomedicine 7, 859 (2011).
34. A. Kunwar, A. Barik, B. Mishra, K. Rathinasamy, R. Pandey, and K. I. Priyadarshini; Quantitative cellular uptake, localization and cytotoxicity of curucmin in normal and tumor cells; Biochim. Biophys. Acta 1780, 673 (2008).
35. D. H. Kim, S. H. Lee, K. H. Im, K. N. Kim, K. M. Kim, I. B. Shim, M. H. Lee, and Y. K. Lee; Surface-modified magnetite nanoparticles for hyperthermia: Preparation, characterization, and cytotoxicity studies; Curr. Appl. Phys. 6s1, e242 (2006).
36. L. M. Bareford and P. W. Swaan; Endocytic mechanisms for targeted drug delivery; Adv. Drug Deliv Rev. 59, 748 (2007).
37. Y. Nagasaki, H. Kobayashi, Y. Katsuyama, T. Jomura, and T. Sakura; Enhanced immunoresponse of antibody mixed-PEG coimmobilized surface construction of high performance immuno-magnetic ELISA system; J. Colloid Interface Sci. 309, 524 (2007).
38. E. L. Lawson, J. G. Clifton, F. Huang, X. Li, D. C. Hixson, and D. Josic; Use of magnetic beads with immobilized monoclonal antibodies for isolation of highly pure plasma membranes; Electrophoresis 27, 2747 (2006).
39. J. H. Lee, Y. M. Huh, Y. W. Jun, J. W. Seo, J. T. Jang, H. T. Song, S. Kim, E. J. Cho, H. G. Yoon, J. S. Suh, and J. Cheon; Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging; Nat. Med. 13, 95 (2007).
40. J. H. Clement, M. Schwalbe, N. Buske, K. Wagner, M. Schnabelrauch, P. Görnert, K. O. Kliche, K. Pachmann, W. Weitschies, and K. Hoffken; Differential interaction of magnetic nanoparticles with tumor cells and peripheral blood cells; J Cancer Res Clin Oncol. 132, 287 (2006).
41. A. Raffaella, R. Simona, P. Rosanna, B. Rita, L. Annalisa, P. Vincenzo, V. Salvatore, and M. F. Romano; Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells; Blood 106, 1400 (2005).
42. N. Zamzami, S. Susin, P. Marchetti, T. Hirsch, I. Gomez-Monterrey, M. Castedo, and G. Kroemer; Mitochondrial control of nuclear apoptosis; J. Exp. Med. 183, 1533 (1996).
43. A. Cossarizza, M. Baccarani-Contri, G. Kalashnikova, and C. Franceschi; A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1); Biochem. Biophys. Res. Commun. 197, 40 (1993).
44. P. Bernardi and V. Petronilli; The permeability transition pores as a mitochondrial calcium release channel: A critical appraisal; J. Bioenerg. Biomembr. 28, 131 (1996).
45. M. Zoratti, and I. Szabo; Electrophysiology of the inner mitochondrial membrane; J. Bioenerg. Biomembr. 26, 543 (1994).